Circulating Endothelial Progenitor Cells and Aortic Aneurysm

Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01918982

Acronym

ANOPEC3

Enrollment

Registered

2013-08-08

Start date

2013-10-31

Completion date

2016-05-31

Last updated

2013-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

- Aortic Aneurysm

Keywords

Aortic aneurysm, circulating endothelial progenitor cells

Brief summary

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Detailed description

Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm \>30mm and \<50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Aortic aneurysm size \>30mm and \> 50mm

Exclusion criteria

* Infectious disease * Inflammatory disease * Liver insuffisency * Cancer evolutive * Pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration	2 years	Patients are followed for 2 years

Contacts

Primary ContactSidney Chocron

sidney.chocron@univ-fcomte.fr+33381533121

Outcome results